PATENT CLAIM ANALYSIS

Application Number: 16082772
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["514", "407000"]

Abstract:
This invention relates to a novel dosage regimen for administration of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof, namely in the treatment of acute exacerbations of inflammatory conditions.

Claim (Index 22):
A method for the treatment of acute exacerbations of an inflammatory disease in a human patient suffering from an inflammatory disease comprising administering to a human patient in need thereof three to five separate therapeutically effective doses of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof over a minimum period of five days and a maximum period of ten days, with at least one day between every dose.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 97.0
- Lexical Diversity: 1.08571
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16082765', '14386174', '11426693', '14088093', '15635268']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7216686634248771
- 35 USC 102 Novelty (BERT): 0.6348073705463775
- Combined Prediction Score: 0.7129825341370272
- Mean Citation Score: 336.049728
- Max Citation Score: 592.7712
- Similarity Product: 541.7302183307648

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test